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Abstract
Mutations of the forkhead transcription factor FOXP2 gene have been implicated in inherited
speech-and-language disorders, and specific Foxp2 expression patterns in neuronal popu-
lations and neuronal phenotypes arising from Foxp2 disruption have been described. How-
ever, molecular functions of FOXP2 are not completely understood. Here we report a
requirement for FOXP2 in growth arrest of the osteosarcoma cell line 143B. We observed
endogenous expression of this transcription factor both transiently in normally developing
murine osteoblasts and constitutively in human SAOS-2 osteosarcoma cells blocked in
early osteoblast development. Critically, we demonstrate that in 143B osteosarcoma cells
with minimal endogenous expression, FOXP2 induced by growth arrest is required for up-
regulation of p21WAF1/CIP1. Upon growth factor withdrawal, FOXP2 induction occurs rapidly
and precedes p21WAF1/CIP1 activation. Additionally, FOXP2 expression could be induced by
MAPK pathway inhibition in growth-arrested 143B cells, but not in traditional cell line models
of osteoblast differentiation (MG-63, C2C12, MC3T3-E1). Our data are consistent with a
model in which transient upregulation of Foxp2 in pre-osteoblast mesenchymal cells regu-
lates a p21-dependent growth arrest checkpoint, which may have implications for normal
mesenchymal and osteosarcoma biology.
Introduction
The FOXP2 forkhead transcription factor was identified in 2001 from independent studies
mapping mutations associated with human inherited speech-and-language disorder and using
homology screening to identify novel forkhead proteins in the mouse lung.[1, 2] FOXP2 shares
characteristics with other members of the FOXP subfamily, including a C-terminal winged
helix forkhead DNA binding domain and is proposed to function predominantly as a
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transcriptional repressor.[1, 3, 4] Consistent with neuro-developmental deficits in humans car-
rying FOXP2mutations, this transcription factor is expressed in multiple specific neuronal
populations in several species.[5–8] Importantly, Foxp2 expression is not neuronally restricted,
having been observed also in normal developing lung epithelium, mesodermal layer of intes-
tine, and cardiac tissues.[1] The related FOXP1 factor is widely expressed in normal and malig-
nant cells[9] and has critical roles during normal development being essential for murine B-
cell production.[10] Unlike FOXP1, FOXP2 expression in normal haematopoietic cells appears
minimal, although we have identified its frequent expression in malignant myeloma cells (B-
cells terminally differentiated into plasma cells) that generally lack FOXP1 expression.[11, 12]
FOXP factors have been linked to regulation of the cell cycle via various mechanisms[13, 14] al-
though not thus far to the cyclin-dependent kinase inhibitor p21WAF1/CIP1, a widely-character-
ised p53 target gene.[15]
To clarify the mechanisms by which FOXP2 contributes to acquisition of intact speech and
language and other developmental functions, multiple research avenues have been pursued.
These include generation of animal models with reduced and/or mutated Foxp2 protein ex-
pression,[16] the introduction of human evolutionary changes into the mouse orthologue[17]
and identification of FOXP2 targets in SH-SY5Y human neuroblastoma and primary neuronal
cells.[3, 4, 18–20] Such studies have established important biological roles for Foxp2 in lung
and neuronal development, including vocalisation, acquisition of motor-skills, auditory pro-
cessing, and learning of auditory-motor associations.[16, 17, 21–26] FOXP2 has thereby been
implicated as a primary controller of multiple diverse cellular pathways, including adhesion,
neurite outgrowth, and neural plasticity.
Given a potential role for FOXP1 in development of bone osteoclasts[27] and expression of
FOXP2 in bone-resident myeloma cells (in which the bone niche has an essential role in disease
pathogenesis and resistance to therapy),[11] we considered whether FOXP2 might play an im-
portant role in bone biology. In accordance with this hypothesis we demonstrate that FOXP2 is
required for regulation of p21WAF1/CIP1 and growth-factor deprivation induced growth arrest of
pre-osteoblast type 143B osteosarcoma cells.
Materials and Methods
Culture of human osteosarcoma cells and normal human osteoblasts
Human osteosarcoma cell lines were obtained from ATCC and cultured in either DMEM sup-
plemented with 2mM L-glutamine and 10% heat-inactivated FBS (143B), McCoy’s 5A supple-
mented similarly (U2-OS), MEM supplemented similarly plus 1x non-essential amino acids
(MG-63) or McCoy’s 5A supplemented with 2mM L-glutamine and 15% heat-inactivated FBS
(SAOS-2, cultured for<20 passages). Addition of 10-7M Vitamin D3 (Sigma, Gillingham UK)
and 10ng/ml TGF-β1 (Peprotech, London UK) to normal growth media was used to differenti-
ate MG-63.[28] Normal human osteoblasts (NHOst) from Lonza (Slough, UK) were cultured
as per supplier instructions. 5T33MM and JJN-3 myeloma cell line controls were cultured in
MEM supplemented with 2mM L-glutamine, 1mM sodium pyruvate, 2x non-essential amino
acids, 50μg/ml 2-mercaptoethanol and 10% heat-inactivated FBS or RPMI supplemented with
10% heat-inactivated FBS respectively. All media were supplied by Life Technologies, Paisley
UK)
Pathway inhibitor experiments
Growing 143B cells were split in parallel to confluency and sub-confluency and four hours
later treated with pathway inhibitors or DMSO vehicle as follows, prior to harvesting for tran-
script analysis 24hr later: PD-98059 MAPK pathway inhibitor at 50 μM, LY-294002 PI3K
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pathway inhibitor at 50 μM, IKK pathway inhibitor VII at 1 μM, Bay 117082 NF-κB pathway
inhibitor at 1 μM, and DBZ Notch signaling inhibitor at 1 μM. All inhibitors were supplied by
Calbiochem (via Millipore, Watford UK) and resuspended in DMSO.
Alkaline phosphatase and MTS assays
Alkaline phosphatase activity in 10μg of whole cell lysate was determined by addition of PNPP
substrate (ThermoFisher Scientific, Loughborough UK) and measurement of absorbance at
405nM. Total viable cell number change was determined by plating cells at 1, 2 or 5 x 103 per
well in duplicate 96-well plates, addition of MTS reagent (Promega, Southampton UK) at 24hr
or 48hr time points and calculation of 490nM absorbance differences over time (following
630nM background correction).
RNA isolation, cDNA preparation and real-time PCR
Total RNA was isolated by either Trizol (LifeTechnologies) or SV total RNA isolation method
(Qiagen, Manchester UK) and 1μg converted to cDNA using Superscript III enzyme (Life-
Technologies). Routinely 1/25th of each cDNA reaction was used per real-time PCR reaction per-
formed in Universal MasterMix II (LifeTechnologies). Taqman assays (all FAM-labelled) were as
follows: Hs_01047977_m1 (RUNX2), Hs_00541729_m1 (SP7/Osterix), Hs_00173720_m1
(IBSP), Hs_00212860_m1 (FOXP1), Hs_00362817 (FOXP2), Hs_00405889_m1 (FOXP4),
Hs_00355782_m1 (CDKN1A/p21), Hs_01597588_m1 (CDKN1B/p27), Hs_00985639_m1 (IL6),
Mm_00475030_m1 (Foxp2) andMm_00446968_m1 (Hprt). VIC-labelled control probes for
human samples were 4319413E (18S), 4326322E (TBP). Human FOXP2 transcript levels were
verified in several experiments using probe Hs_00362818_m1. Normalisation was routinely per-
formed using both 18S and TBP to confirm target gene effects (18S data shown).
Protein extract preparation and immunoblot analyses
Whole cell extracts from cultured cells were prepared in 10mMHEPES pH7.9, 400mMNaCl,
0.1mM EDTA, 5% glycerol and protease inhibitors after snap freezing, and quantitated by
BCA assay (ThermoFisher Scientific). Nuclear extracts from fresh cultures were prepared using
an extraction kit (Affymetrix, High Wycombe UK). Protein was extracted from murine bone
by Trizol method. 10–40μg of lysate was subjected to immunoblot analysis by standard tech-
niques after 12% SDS-PAGE using primary antibodies as per S1 Table.
Chromatin immunoprecipitation analyses
Chromatin immunoprecipitation using anti-FOXP2 73A/8, (MABE415 Merck Millipore, Wat-
ford UK) and control MR12 antibodies was performed using standard techniques. Briefly,
chromatin was prepared from approximately 3 x 107 confluent or serum-starved 143B cells by
formaldehyde cross-linking, lysis in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-
HCL pH8.0) and 10 cycles of sonication. After clearing of the lysate by centrifugation, and
dilution 1:5 into dilution buffer (0.01% SDS, 1% Triton X-100, 2 mM EDTA, 150 mMNaCl,
20 mM Tris-HCl pH 8.0), overnight incubations with 5μg antibody were performed. Immune
complexes were collected on Protein A/G-plus agarose (Santa Cruz, Heidelberg, Germany),
washed and then eluted into 1% SDS, 0.1M NaHCO3. Cross-links were reversed at 65°C,
RNAse and proteinase K digestion performed, samples phenol-chloroform extracted and DNA
purified into 100 μl T.E. 1 μl template was used for 30 cycles of PCR amplification with specific
primers using GoTaq DNA polymerase (Promega). Amplification from a 1% input sample was
performed in each case for comparison.
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Flow cytometric analysis of cell cycle distribution
Cell cycle status by distribution of DNA content was determined by flow cytometric analysis
(FACScalibur, BD Biosciences, Oxford UK) after fixation in 70% EtOH and resuspension in
phosphate-buffered saline containing 0.1% sodium citrate, 0.1% Triton X-100 and 50μg/ml
propidium iodide. Data were analysed using FlowJo software.
siRNA transfection
Human osteosarcoma cells were plated in 6-well dishes at 2 x 105 per well and transfected with
Stealth siRNAs, either low GC control duplex 1 (siLGC), FOXP2 siRNA duplex 1 (P2si#1, tar-
geted sequence 50-GAC-AGG-CAG-TTA-ACA-CTT-AAT-30), or FOXP2 siRNA duplex 2
(P2si#2, targeted sequence 50-GCG-ACA-GAG-ACA-ATA-AGC-AAC-AGT-T-30), using
RNAiMax reagent (all LifeTechnologies). In some experiments additional control LGC du-
plexes were used to verify effects.
Immunohistochemistry of Foxp2 expression
Embryos were formalin fixed, sectioned, and paraffin-embedded slides dewaxed and antigen
retrieved by microwaving in 50mM Tris, 2mM EDTA pH9.0, with anti-FOXP2 73A/8 or
MR12 antibody (1:1000) subsequently applied overnight at 4°C and the NovoLink polymer
system used for detection (LeicaBiosystems, Milton Keynes UK).
Statistical testing
Statistical testing for significance (indicated where p0.05 by asterisk) in all experiments was
performed by Student’s t-test.
Results
Foxp2 is the Foxp factor most highly expressed in murine bone
We have previously observed FOXP2 expression in multiple myeloma,[11] a plasma cell malig-
nancy that is known to interact with the bone microenvironment and cause devastating lytic
bone disease in patients.[29] The osteoblast transcription factor RUNX2 is also expressed in
myeloma[30] and we hypothesised that similarly FOXP2 might play a role in normal bone
biology.
Preliminary data-mining analysis of Foxp2 gene expression patterns in normal tissues using
www.biogps.org identified potentially high-level Foxp2 transcript expression in osteoblasts
from multiple probesets 1422014_at, 1438231_at, 1438232_at and 1440108_at (data not
shown). We confirmed this expression profile of Foxp2 transcripts in murine bone (Fig 1A),
and found it to contrast with expressions of Foxp1 and Foxp4 (Fig 1B). To measure Foxp2 ex-
pression in normal osteoblast development we studied normal E17.5 long bone after validating
our anti-FOXP2 73A/8 monoclonal antibody for Foxp2 reactivity and specificity against the
widely expressed murine Foxp proteins (Fig 1C). We found strong nuclear expression of Foxp2
in periosteal cells at the bone collar (Fig 1D panels i and iii), but not in more mature osteoblasts
located towards the centre of the periosteum (Fig 1D panel ii). Consistent with a recent report
[31] weak Foxp2 expression was also present in proliferating chondrocytes (S1 Fig). Combined,
these data suggest FOXP2 to be the most important FOXP factor for bone biology.
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Fig 1. Foxp2/FOXP2 expression in murine bone and association with reduced growth of osteosarcoma cell lines. (A,B) Real-time PCR analysis of
gene expression in primary murine tissues from 12-week old male C57Bl/6 mice using SyBr-green, specifically whole bone marrow (BM), spleen (Spl),
thymus (Thy), whole long bones after flushing and 2 rounds of collagenase digestion (Bone) and bone-associated cells from the collagenase fraction (CF).
Data represent mean +/- SD of three mice. While Foxp1 and Foxp4 are most expressed in CD45+ haematopoietic tissues, Foxp2 expression is highest in
bone as are the established osteoblast genes Ibsp and Sp7. Expression normalised to Hprt, expressed relative to highest sample (100%); (C) Immunoblot
analysis of COS-1 fibroblast-like cells transiently transfected with CMV-driven mammalian expression plasmids containing murine full-length Foxp cDNAs or
pCDNA4 empty vector (control) as indicated top. All antibodies exhibited specificity for appropriate ectopically-expressed proteins, low level endogenous
FOXP4 expression was detectable in all lysates; (D) Immunohistochemical detection of Foxp2 protein in murine E17.5 long bone, detail (middle panels)
showing variation in Foxp2 positivity along the periosteum, staining with the anti-rabbit murine monoclonal antibody MR12 was performed on serial sections
as negative control (same regions, right panels)
doi:10.1371/journal.pone.0128513.g001
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FOXP2 is expressed in SAOS-2 cells and induced by growth arrest in
MG-63
To further investigate FOXP2 expression in cells with osteoblast characteristics in vitro we ex-
amined established murine MC3T3-E1 and C2C12 systems for Foxp2 expression. However, ex-
pression of Foxp2 was extremely low and was not regulated significantly by the differentiation
stimulus in either system (data not shown). Thus a series of human osteosarcoma cell lines
whose differentiation are blocked during pre-osteoblast mesenchymal development was inves-
tigated. Of these, SAOS-2 exhibit the slowest growth and significant alkaline phosphatase activ-
ity (key characteristics of osteoblasts), along with expression of hallmark osteo-lineage genes
RUNX2 (bone-specific isoform,[32]) Osterix/SP7, and integrin-binding sialoprotein IBSP (Fig
2A–2C). These data indicate that SAOS-2 exhibit a committed osteoblast phenotype being
more mature than 143B, MG-63 or U2-OS. Interestingly, this state is associated with robust
FOXP2 expression at both the transcript and protein levels (Fig 2D and 2E). Given the paucity
of literature on FOXP expression in the osteoblast lineage, FOXP2 expression was confirmed
using multiple antibodies (Fig 2E) and additional real-time PCR assays (amplifying Exons 14–
15 and Exons 16–17 respectively, data not shown). FOXP4 levels across the panel were relative-
ly constant while FOXP1 expression was lowest in U2-OS and SAOS-2. Consistent with data
from the embryonic murine bone, normal mature human osteoblasts from multiple donors did
not express significant FOXP2 transcripts or protein (Fig 2F and data not shown)
To investigate whether FOXP2 expression might define a more committed stage of osteo-
blast development we used an established protocol[28] to promote differentiation of MG-63
cells, thereby inducing growth arrest and alkaline phosphatase expression, while monitoring
FOXP2 expression (Fig 2G–2I). The combined Vitamin D3 and TGF-β treatment, which ar-
rested cell growth at sub-confluence and induced alkaline phosphatase activity (Fig 2G and
2H), did not induce FOXP2 (Fig 2I). Interestingly, the vehicle-treated cells, which became
growth arrested by confluence at the end of the experiment showed an approximately 7-fold
significant increase in FOXP2 expression after 48h (Fig 2I).
Confluent growth arrest is associated with increased FOXP2 expression
To determine the wider applicability of confluent growth arrest (rather than terminal differen-
tiation) in FOXP2 induction, cell lines with minimal basal FOXP2 expression (MG-63, 143B,
U2-OS) were cultured to confluency (Fig 3). Confluence was associated with growth arrest
and minimal apoptosis (143B data shown as example, Fig 3A and 3B), even after 4 days and
significant, up to 20-fold, induction of FOXP2 transcripts in all cell lines (p<0.05 for both
early and late arrest states Fig 3C). Expression of other FOXP family members (FOXP1 and
FOXP4) remained relatively unaffected (Fig 3C), the only significant effect being weak FOXP1
induction in both U2-OS arrest samples (p<0.05). Parallel immunoblotting analyses validated
robust FOXP2 protein increases by confluence in 143B cells (Fig 3D), although not in MG-63
and U2-OS cells where background FOXP2 transcription is low (Fig 2D) Inhibition of CDK ki-
nase activity during growth arrest is critical for reduction of pRb levels and/or its phosphoryla-
tion and resulting decreases in E2F transcription factor availability. This CDK inhibition is
dependent upon several cyclin-dependent kinase inhibitors (CKIs) including CDKN1A/
p21WAF1/CIP1 and CDKN1B/p27KIP1 (for review see [33]). While VitD3/TGFβ-dependent MG-
63 differentiation occurred in the absence of cell-cycle dependent kinase inhibitor p21CIP1/WAF1
and p27KIP1 up-regulation (S2 Fig), induction of full-length FOXP2 in confluent 143B cells was
coincident with strongly induced p21CIP1/WAF1 and more weakly induced p27KIP1 transcripts
(p<0.05, Fig 3E).
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Fig 2. FOXP2 is expressed in SAOS-2 cells and induced by growth arrest in MG-63. (A) Total viable cell number determined by MTS assay (absorbance
at 490nm) in cell lines 143B, MG-63, U2-OS and SAOS-2 growing exponentially in vitro, after plating at equal cell numbersN = 3 ± SD; (B) Alkaline
phosphatase activity by PNPP assay (absorbance at 405nm) in whole cell lysates,N = 3 ± SD; (C) Real-time PCR analyses of gene expressions as
indicated, expression shown as percentage relative to highest (100%)N = 3 ± SD; (D) Real-time PCR analyses of FOXP expression as indicated, expressed
as 2-δδCT, relative to 143B,N = 3 ± SD; (E) Immunoblot analyses of nuclear extracts from exponentially growing cell lines, including nucleophosmin (NPM) as
a loading and transfer control, representative of two experiments; (F) Real-time PCR analysis of human FOXP2 expression in NHOst cultures from two
individuals, expressed as 2-δδCT, relative to expression in SAOS-2 sample, parallel immunoblot analysis did not detect FOXP2 in NHOst cultures (not shown);
(G) Phase contrast images of MG-63 cultures plated subconfluently and cultured for 48hr in presence of vehicle alone or Vitamin D3 plus TGF-β to induce
osteoblast differentiation; (H) Alkaline phosphatase activity in lysates from cells in H and SAOS-2 positive control; (I) Real-time PCR analyses of FOXP2
expression in MG-63, relative to 2hr vehicle sample, all MG-63 differentiation data representative of two experiments.
doi:10.1371/journal.pone.0128513.g002
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Fig 3. Confluent growth arrest is associated with increased FOXP2 expression. (A) Cell cycle analysis of 143B subjected to increasing confluence
(approximate percentage confluence indicated top), numbers within plots from left to right indicate percentage of cells in G1/G0, S, and G2/M phase
respectively, representative of three experiments; (B) Quantitation of apoptotic cell death in 143B cell populations by flow cytometric analysis of Annexin V
positivity, in cultures either exponentially growing (Exp. Growth), subjected to overnight culture with 20μg/ml cyclohexmide as a positive control that induces
apoptosis (cycloheximide), or subjected to 4 days growth arrest at confluence (late arrest, as per A). Numbers represent mean% annexin positive ± SD from
three experiments; (C) Real-time PCR analyses of FOXP expression in MG-63, 143B and U2-OS cultured to increasing confluence, expressed as 2-δβCT,
relative to growing culture,N = 3 ± SD; (D) Immunoblot analyses of nuclear extracts from cells cultured as inC, including nucleophosmin (NPM) as a loading
and transfer control, representative of two experiments, (E) Real-time PCR analyses of p21, p27 and IL-6 expression in 143B cultured to increasing
confluence, expressed as 2-δδCT, relative to growing culture,N = 3 ± SD.
doi:10.1371/journal.pone.0128513.g003
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Growth arrest-induced FOXP2 transcription is upstream of the cell-cycle
machinery
We considered that induction of FOXP2 by cell confluence might be a consequence either of
growth arrest or increased cell-cell interactions as a consequence of cell density (or both).
When 143B growth was inhibited at sub-confluence by five days’ serum restriction (Fig 4A),
rather than contact inhibition, FOXP2 induction was maintained (p<0.05, Fig 4B), indicating
this to be a growth-inhibition rather than cell-cell contact related phenomenon. Low serum
treatment was also associated with significant increases in p21WAF1/CIP1 transcript levels
(p<0.05, Fig 4B). Growth arrest of 143B in G1/0, induced by the downstream Cyclin-Depen-
dent Kinase (CDK) inhibitor Palbociclib,[34] (Fig 4C) was not associated with FOXP2 induc-
tion or that of p21WAF1/CIP1 (Fig 4D), indicating FOXP2 induction to be an upstream primary
event rather than secondary to growth arrest. Experiments to determine the temporal relation-
ship between FOXP2 and p21WAF1/CIP1 induction after serum starvation demonstrated early in-
creases in FOXP2 transcript levels prior to p21CIP1/WAF1 induction (Fig 4E). Specifically,
FOXP2 induction was significant at 8, 24, 36 and 48 hr timepoints, while p21CIP1/WAF signifi-
cant only at 48hr. In an attempt to block the FOXP2 induction by confluence, experiments
were repeated with the addition of various chemical inhibitors of biological signalling path-
ways. While no inhibitor blocked FOXP2 induction, ERK1/2 pathway inhibition using PD-
98059 significantly increased FOXP2 induction approximately 2-fold (Fig 4F p = 0.03, and Fig
4G), providing further evidence for loss of proliferation signals driving FOXP2 expression.
FOXP2 induction is required for efficient 143B growth arrest and
p21 CIP1/WAF1 upregulation
To understand the importance of FOXP2 induction for confluent growth arrest, 143B cells
were treated with FOXP2-targeting or control siRNAs at sub-confluence and then, after being
grown to confluence, cell morphology and cell cycle status were monitored (Fig 5). Efficient
and specific targeting of FOXP2 at the protein level was achieved and was associated with some
increases in FOXP1 and FOXP4 expression, which might be via a compensatory mechanism
(Fig 5A). Under these conditions FOXP2 depletion was associated with reduced growth arrest
as determined by significantly reduced changes in G1/0 and G2/M (p<0.05 for both siRNAs,
Fig 5B) and increased cell density (Fig 5C).
Following both confluent and low-serum growth arrest we observed CDKN1A/p21 to be in-
duced in 143B cells (Figs 3E, 4B and 4E). Timecourse experiments under serum starvation al-
ready indicated FOXP2 induction occurs earlier than CDKN1A and critical FOXP2 depletion
experiments showed that the majority of CDKN1A transcript induction by confluence is
FOXP2-dependent (expression after either FOXP2 siRNA significantly lower than control
p<0.001, Fig 5D). At the protein level, FOXP2 depletion reduced p21 protein induction and
consequential total Rb downregulation whilst leaving total p53 and CDK4 levels largely unal-
tered (Fig 5E, although CDK4 expression in some experiments as shown here was slightly re-
duced). In addition, CDKN1A/p21 expression induced by serum deprivation was also partially
FOXP2-dependent (both siRNAs p0.05, Fig 5F).
Mechanistically, in accordance with positive regulation of p21 by IL-6 in osteoblastic cells
[35], also IL-6 expression was induced under confluent conditions (Fig 3E). However, addition
of exogenous IL-6 did not rescue p21 decreases or morphology changes induced by FOXP2 de-
pletion (Fig 5G), indicating control of p21 by FOXP2 to be independent of IL-6. Given interac-
tions between other FOXP family members and the p53 pathway[36, 37] and induction of the
CDKN1A transcriptional regulator p53 during growth arrest of 143B (Fig 5E), a specific re-
quirement for FOXP2 in p53-dependent p21 transcription was examined. Importantly, in
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Fig 4. Growth arrest-induced FOXP2 transcription is upstream of the cell cycle machinery. (A, C) Cell cycle analyses of 143B grown for 6 days in
reduced serum or 1 day in the CDK4/6 inhibitor Palbociclib 100 nM or 1 μM as indicated; (B, D) Real-time PCR analyses of gene expression in 143B cultured
as in A andC, expressed as 2-δδCT, relative to growing or vehicle-treated culture,N = 3 ± SD; (E) Real-time PCR analyses of gene expression in 143B
reduced serum experiments similar to A over a shorter timecourse,N = 3 ± SD; (F) Real-time PCR analysis of FOXP2 expression in 143B cultured at
subconfluence or confluence for 24hrs in the presence of inhibitors/vehicle as indicated, (PD-98059 ERK1/2 inhibitor and LY-294002 PI3K inhibitor at 50μM,
IKK inhibitor 7, Bay117082 NFκB inhibitor, and DBZ Notch pathway inhibitor at 1μM), expressed as fold change induced by confluence, inhibitors had
minimal effect on subconfluent FOXP2 expression,N = 5 ± SD; (G) Immunoblot analysis of nuclear extracts from 143B treated at confluence as in F, including
nucleophosmin (NPM) as a loading and transfer control.
doi:10.1371/journal.pone.0128513.g004
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Fig 5. FOXP2 induction is required for efficient 143B growth arrest and p21 CIP1/WAF1 control. (A) Immunoblot analysis of FOXP expression in nuclear
extracts from confluent 143B cells 48hr after siRNA transfection, including TATA-binding protein (TBP) as a loading and transfer control, representative of
three experiments; (B) Quantitation of changes in cell cycle fractions induced by confluence as per A, relative to dividing cells,N = 3 ± SD; (C) Phase contrast
images of cells as in A, to show frequently increased saturation density following FOXP2 depletion;; (D) Real-time PCR analysis of p21/CDKN1A expression
in 143B cultured as in A, expressed as 2-δδCT, relative to subconfluent culture (T = 0), control is mean of four different control siRNAs. N = at least 4 ± SD; (E)
Immunoblot analyses of whole cell lysates from cells cultured as in A; (F) Real-time PCR analysis of p21CDKN1A expression in cells transfected at
subconfluence (T = 0) with siRNAs as shown and harvested still at subconfluence after 48 hr culture in 1% serum, N = 3 ± SD; (G) Real-time PCR analysis of
p21CDKN1A expression in and phase contrast images of cells cultured as in A, in the presence of either 10ng/ml hIL-6 (+ IL-6) or PBS/BSA carrier alone
FOXP2 Function in Mesenchymal Growth Arrest
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subconfluent 143B cells which are p53mutant[38, 39] induction of p21 transcription by ectopic
expression of wild-type p53 did not upregulate FOXP2 and FOXP2 siRNA, demonstrating that
this p21 induction by p53 was independent of the basal FOXP2 expression present in exponen-
tially growing cells (Fig 5H).
In order to understand further how FOXP2 might control p21, if not via regulation of IL-6
expression or p53 activity, chromatin immunoprecipitation on lysates from growth arrested
143B cells was performed using control and anti-FOXP2 antibodies and multiple primer pairs
proximal to 14 clusters of potential FOXP binding sites within 10Kb upstream or downstream
of the p21/CDKN1A transcription start site. Despite efficient FOXP2 immunoprecipitation
using the 73A/8 monoclonal antibody under ChIP conditions, binding of FOXP2 at specific
sites in the p21 locus was not reliably detected (S3 Fig). These data, together with an absence of
p21/CDKN1A from published lists of direct FOXP2 target genes in other systems,[3, 4, 19] indi-
cate a likely indirect mechanism for FOXP2-dependent control of p21 transcription.
In summary, our expression and functional data implicate FOXP2 as a transient regulator
of growth arrest via indirect control of p21WAF1/CIP1 at an early stage of pre-osteoblast
mesenchymal development.
Discussion
Studies over the last fifteen years have established FOXP2 as a molecule important for neurobi-
ology, particularly in the acquisition of speech and language as evidenced by its mutation in
families with inherited speech and language disorders.[2, 8] However, expression of FOXP2 is
not restricted to neuronal populations, and is important for example also in lung epithelial de-
velopment in the mouse.[23] Here we have shown that FOXP2 is expressed in developing oste-
oblasts and have demonstrated that FOXP2 can promote growth arrest and therefore likely
control differentiation by regulating expression of the critical cell-cycle inhibitor p21WAF1/CIP1.
These findings, together with those of Zhao et al [31] add FOXP2 to the list of established
osteoblast and chondrocyte transcription factors such RUNX2,Osterix and SOX9 [40, 41] and
it will be interesting in the future to investigate the interplay between FOXP2 and these factors,
and understand their potential role in regulation of p21 expression alongside Foxp2. It is po-
tentially noteworthy that Foxp2 expression in developing embryonic bone may be increased by
Runx2 deletion (GEO profile GDS2185 / 164118_at / Foxp2), with the stage of developmental
block in Runx2-/- bone potentially being defined by the induction of Foxp2 expression. Further-
more the induction of FOXP2 in 143B growth arrest is associated with induction of the chon-
drocyte transcription factor SOX9 (unpublished data). It is also likely that additional
transcription factors interplay with Foxp2 in developing bone, and we note that deficiency of
the Lim-domain factor Lhx8, whose expression is most closely correlated with that of Foxp2 in
murine tissues (both osteoblast and neuronal expression- www.biogps.org), causes cleft palate
and molar deficiencies in mouse models.[42, 43]
We have identified that FOXP2 expression is associated with that of both p21WAF1/CIP1 and
IL-6, whose importance and interplay in osteoblast lineage cells has been studied previously.
[35, 44, 45] However, in contrast to previous findings,[35] our data show that exogenous IL-6
cannot rescue reductions in p21WAF1/CIP1 expression following FOXP2 depletion. These data
indicate that FOXP2-dependent regulation of p21WAF1/CIP1 in osteoblast lineage cells is inde-
pendent of IL-6. Given that multiple published FOXP2 ChIP studies have not identified bind-
ing to the CDKN1A locus, and that also our data do not support FOXP2 binding to a discrete
(—IL-6); (H) Real-time PCR analyses of cells transfected at subconfluence with p53 cDNA plasmid or empty control plasmid (vector), then treated with siLGC
or each FOXP2 siRNA and harvested still at subconfluence after 48hr culture in 10% serum. Expression is shown as percentage relative to highest (100%).
doi:10.1371/journal.pone.0128513.g005
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CDKN1A region, further studies will be required to identify indirect mechanisms by which
FOXP2 controls p21 transcription. One possible intermediate is MEF2D, which has been iden-
tified both as a FOXP2 target[3] and recently as a direct regulator of p21/CDKN1A transcrip-
tion.[46] Given the importance of p21WAF1/CIP1 expression in neuronal development (for
example, Marques-Torrejon et al[47]), control of p21 by Foxp2 is likely to play an important
role in controlling neuronal differentiation. Interestingly, based on data from genome-wide ex-
pression profiling experiments, p21/CDKN1A levels in SH-SY5Y cells ectopically expressing
human FOXP2 protein are significantly higher than in SH-SY5Y cells ectopically expressing
the chimp orthologue,[18] suggesting the possibility of altered FOXP2-p21 regulation during
human evolution. Regarding the RUNX-2-dependent pathway for FOXP function in mesen-
chymal lineage proposed by Zhao et al[31] our data for active FOXP2 function in 143B cells
demonstrate that the bone-specific isoform of RUNX2, which these cells lack, is not a require-
ment for FOXP2 function.
A recent in vivo knockout study[31] has demonstrated that the control of chondrocyte and
osteoblast development by Foxp proteins is a complicated process, and it is evident that of the
Foxp factors, Foxp2 loss has arguably the greatest disruptive effects on normal chondrocyte
and osteoblast biology. We have successfully identified 143B cells as a complimentary tractable
in vitromodel system for studying FOXP2 and p21WAF1/CIP1 co-regulation in mesenchymal
growth arrest, which will enable further studies to more quickly elucidate mechanisms for
FOXP2 function. While similar treatment of additional osteosarcoma lines induces FOXP2
transcripts, upregulation of FOXP2 protein is limited (Fig 3), and confluent growth arrest of
the neuroblastoma line SH-SY5Y does not induce FOXP2 transcripts (data not shown). We
speculate that as for RUNX2 in osteosarcoma,[32] the expression and/or function of FOXP2 in
malignant cells may be frequently compromised, which may explain the lack of overt growth
arrest phenotype and induction of p21WAF1/CIP1 in SH-SY5Y cells stably engineered to over-ex-
press recombinant FOXP2.[3, 4] Alternatively, FOXP2 may require one or more co-operating
factors to initiate growth arrest in normal developing populations. This would be consistent
with a model in which established specific pro-osteoblast signals (such as BMPs driving
RUNX2 but not FOXP2) function synergistically with signals triggered by loss of growth sig-
nalling activity (such as FOXP2 after MAPK pathway inhibition). Indeed, important interac-
tions between Foxp3 and Runx family proteins have been demonstrated previously in
hematopoietic cells[48] and also between Foxps and Runx2 recently in murine bone.[31]
Our expression studies suggest that in developing murine mesenchymal cells the loss of
growth factor signalling upon entry to the periosteum might up-regulate Foxp2. Expression of
Foxp2 during both osteoblast and some neuronal development appears to be transient (this
manuscript and for example Rousso et al[20]). This is also observed for other family members,
for example transient FOXP3 induction in activated human T-cells[49] in contrast to main-
tained FOXP3 expression in regulatory T-cell populations.[48] Such temporal restriction in
specific populations may relate to renewal of (alternate) growth signalling at later stages of de-
velopment, or negative FOXP2 autoregulation once growth arrest function has been
completed.
Given the importance of the growth arrest gene p21WAF1/CIP1 as a p53 target[15] and the
roles of p53 in osteoblast development and osteosarcoma[50, 51] we considered potential con-
nections between FOXP2 and p53 pathways, as have been demonstrated for the related FOXP1
and FOXP3 proteins.[36, 37] However, thus far the lack of correlation between FOXP2 expres-
sion and p53 status in cell lines (143B mutant, MG-63 null, U2OS wild-type, SAOS-2 null), ab-
sence of FOXP2 expression changes upon p53 overexpression, and lack of requirement for
FOXP2 in p53-dependent p21 activation indicate that FOXP2 and p53 function independently
to regulate one or more common targets such as p21. Given the recent identification of SOX2
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inhibition by p21,[47] our findings provide a potentially novel mechanism for the published in-
verse relationship of Sox2 with Foxp2 in developing motor neurons.[20]
Our findings have implications not only for normal development but also human disease.
Normal osteoblast development is compromised in bone metastases of solid tumours and in
bone malignancies such as multiple myeloma, and thus characterisation of FOXP2 growth ar-
rest function in a disease context may identify novel malignant pathways. Furthermore,
FOXP2 status in osteosarcoma may provide information regarding the stage of developmental
block, with potential clinical significance. Direct connection of FOXP2 to the mutated p53
pathway in osteosarcoma, via a common target p21/CDKN1A, is also likely to have implica-
tions for understanding osteosarcoma biology.
Supporting Information
S1 Table. Details of antibodies used in this study.
(TIF)
S1 Fig. Weak Foxp2 expression in proliferating embryonic murine chondrocytes. Detail of
images partly shown in Fig 1, immunohistochemical detection of Foxp2 protein in murine
E17.5 long bone, demonstrating weak but significant Foxp2 positivity in proliferating chondro-
cytes (at the location indicated by arrow). Staining with the anti-rabbit murine monoclonal an-
tibody MR12 was performed on serial sections as negative control.
(TIF)
S2 Fig. Growth arrest and differentiation of MG-63 occurs without induction of p21 and
p27 transcripts. Real-time PCR analyses of p21 expression (A) and p27 expression (B) in MG-
63, relative to 2hr vehicle sample.
(TIF)
S3 Fig. Attempted immunoprecipitation of FOXP2 on the human p21WAF/CIP locus. (A)
Initially, confluent 143B cell lysates were immunoprecipitated with MR12 or 73A/8 FOXP2 an-
tibodies as indicated, washed as per ChIP protocol and precipitated complexes analysed by im-
munoblot for presence of FOXP2 protein. (B) Co-precipitated chromatin from similar
experiments was used as template for amplification of fragments of the human p21WAF1/CIP
locus. Site labelled ‘con’ was chosen as a negative control, being (within the 40kb analysed) the
greatest distance away from predicted FOXP binding sites. Although some apparent FOXP2
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